BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29980453)

  • 1. Adherence to Treatment Guidelines in Heart Failure Patients in the Top End Region of Northern Territory.
    Mu M; Majoni SW; Iyngkaran P; Haste M; Kangaharan N
    Heart Lung Circ; 2019 Jul; 28(7):1042-1049. PubMed ID: 29980453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction.
    Kane JA; Kim JK; Haidry SA; Salciccioli L; Lazar J
    Cardiology; 2017; 137(2):121-125. PubMed ID: 28376504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.
    Güder G; Störk S; Gelbrich G; Brenner S; Deubner N; Morbach C; Wallenborn J; Berliner D; Ertl G; Angermann CE
    Eur J Heart Fail; 2015 Apr; 17(4):442-52. PubMed ID: 25727879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure.
    Bertero E; Miceli R; Lorenzoni A; Balbi M; Ghigliotti G; Chiarella F; Brunelli C; Viazzi F; Pontremoli R; Canepa M; Ameri P
    Intern Emerg Med; 2019 Oct; 14(7):1083-1090. PubMed ID: 30835055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart failure medication dosage and survival in women and men seen at outpatient clinics.
    Bots SH; Onland-Moret NC; Tulevski II; van der Harst P; Cramer MJM; Asselbergs FW; Somsen GA; den Ruijter HM
    Heart; 2021 Nov; 107(21):1748-1755. PubMed ID: 34261736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doses of renin-angiotensin system inhibitors but not beta-blockers predict outcome after ST-elevation myocardial infarction.
    Liu PY; Chen CL; Yu MC; Ko YL; Hsu SY; Chou HH; Yeh KH; Duan DM; Chen MH; Lin JF
    Acta Clin Belg; 2019 Oct; 74(5):334-341. PubMed ID: 30295167
    [No Abstract]   [Full Text] [Related]  

  • 7. Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction.
    Chen X; Cui X; Thunström E; Pivodic A; Dahlström U; Fu M
    Clin Res Cardiol; 2021 Jul; 110(7):1051-1062. PubMed ID: 33394127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry.
    Chang HY; Wang CC; Wei J; Chang CY; Chuang YC; Huang CL; Chong E; Lin JL; Mar GY; Chan KC; Kuo JY; Wang JH; Chen ZC; Tseng WK; Cherng WJ; Yin WH
    J Chin Med Assoc; 2017 Dec; 80(12):750-757. PubMed ID: 29033112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34).
    Chan D; Doughty RN; Lund M; Lee M; Kerr AJ
    Heart Lung Circ; 2020 Sep; 29(9):1386-1396. PubMed ID: 32423781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart failure clinics improve use of evidence-based heart failure therapies in patients with reduced ejection fraction following acute coronary syndrome (ANZACS-QI 48).
    Chan D; Doughty RN; Mazengarb J; McLachlan A; Kerr AJ
    N Z Med J; 2020 Jun; 133(1516):58-71. PubMed ID: 32525862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
    Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Heart Failure With Chronic Kidney Disease - Propensity Score Matching Analysis.
    Kim HJ; Lee MH; Jo SH; Seo WW; Kim SE; Kim KJ; Choi JO; Ahn HS; Choi DJ; Ryu KH
    Circ J; 2019 Dec; 84(1):83-90. PubMed ID: 31776309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
    Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
    Gilstrap LG; Fonarow GC; Desai AS; Liang L; Matsouaka R; DeVore AD; Smith EE; Heidenreich P; Hernandez AF; Yancy CW; Bhatt DL
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28189999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease.
    Lipworth B; Skinner D; Devereux G; Thomas V; Ling Zhi Jie J; Martin J; Carter V; Price DB
    Heart; 2016 Dec; 102(23):1909-1914. PubMed ID: 27380949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
    Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
    JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker adherence in patients with primary versus secondary diagnosis of heart failure.
    Brackbill ML; Bashaw-Keaton R; Sytsma CS
    Am J Manag Care; 2007 Oct; 13(10):568-70. PubMed ID: 17927461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical therapy doses at hospital discharge in patients with existing and de novo heart failure.
    Diamant MJ; Virani SA; MacKenzie WJ; Ignaszewski A; Toma M; Hawkins NM
    ESC Heart Fail; 2019 Aug; 6(4):774-783. PubMed ID: 31218850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Prognostic Impact of Early Treatment with Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients with Acute Heart Failure.
    Yoshioka K; Matsue Y; Yamaguchi T; Kitai T; Kagiyama N; Okumura T; Kida K; Oishi S; Akiyama E; Suzuki S; Yamamoto M; Kuroda S; Matsumura A; Hirao K
    Am J Cardiovasc Drugs; 2019 Dec; 19(6):597-605. PubMed ID: 31218508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.